ZNF609 Knockout cell line (A-375)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZNF609 (zinc finger protein 609) encodes a zinc finger protein predicted to bind promoter-associated chromatin and regulate gene expression. It is involved in regulation of myoblast proliferation and is localized primarily in the nucleoplasm. ZNF609 is therefore relevant to studies of transcriptional regulation, chromatin interactions, muscle cell biology, and mechanisms controlling myoblast proliferation.

The A375 cell line is a highly characterized human malignant melanoma model derived from a 54-year-old female patient. As referenced in image_2f51f1.png, this adherent cell line demonstrates robust translational performance in in vivo xenograft studies, reliably producing rapidly growing amelanotic melanomas when inoculated into anti-thymocyte serum-treated NIH Swiss mice. Serving as a globally recognized preclinical oncology platform, it is extensively utilized for investigating melanoma disease progression, executing high-throughput screening of novel therapeutics, and studying targeted signaling pathways in skin cancers.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.